Susquehanna International Group’s CorMedix CRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.26M | Sell |
922,200
-854,900
| -48% | -$6.32M | ﹤0.01% | 3853 |
|
|
2025
Q4 | $20.7M | Buy |
1,777,100
+690,300
| +64% | +$7.63M | ﹤0.01% | 2166 |
|
|
2025
Q3 | $12.6M | Buy |
1,086,800
+524,100
| +93% | +$6.34M | ﹤0.01% | 2735 |
|
|
2025
Q2 | $6.93M | Buy |
562,700
+437,400
| +349% | +$4.83M | ﹤0.01% | 3390 |
|
|
2025
Q1 | $772K | Sell |
125,300
-178,400
| -59% | -$1.85M | ﹤0.01% | 7909 |
|
|
2024
Q4 | $2.46M | Buy |
303,700
+246,900
| +435% | +$2.47M | ﹤0.01% | 4848 |
|
|
2024
Q3 | $459K | Buy |
+56,800
| New | +$307K | ﹤0.01% | 8667 |
|
|
2024
Q2 | – | Sell |
-62,700
| Closed | -$266K | – | 12176 |
|
|
2024
Q1 | $266K | Sell |
62,700
-34,200
| -35% | -$119K | ﹤0.01% | 9981 |
|
|
2023
Q4 | $364K | Buy |
96,900
+49,000
| +102% | +$169K | ﹤0.01% | 9404 |
|
|
2023
Q3 | $177K | Sell |
47,900
-1,400
| -3% | -$5.57K | ﹤0.01% | 10362 |
|
|
2023
Q2 | $196K | Sell |
49,300
-48,200
| -49% | -$238K | ﹤0.01% | 10294 |
|
|
2023
Q1 | $404K | Buy |
97,500
+56,400
| +137% | +$231K | ﹤0.01% | 9079 |
|
|
2022
Q4 | $173K | Buy |
41,100
+26,000
| +172% | +$92K | ﹤0.01% | 10319 |
|
|
2022
Q3 | $43K | Buy |
15,100
+4,300
| +40% | +$17.9K | ﹤0.01% | 12291 |
|
|
2022
Q2 | $43K | Sell |
10,800
-32,000
| -75% | -$119K | ﹤0.01% | 12051 |
|
|
2022
Q1 | $235K | Buy |
42,800
+10,200
| +31% | +$46.7K | ﹤0.01% | 10848 |
|
|
2021
Q4 | $148K | Sell |
32,600
-43,900
| -57% | -$218K | ﹤0.01% | 11805 |
|
|
2021
Q3 | $356K | Sell |
76,500
-44,800
| -37% | -$261K | ﹤0.01% | 10207 |
|
|
2021
Q2 | $832K | Sell |
121,300
-41,000
| -25% | -$326K | ﹤0.01% | 8268 |
|
|
2021
Q1 | $1.62M | Buy |
162,300
+121,700
| +300% | +$1.28M | ﹤0.01% | 6438 |
|
|
2020
Q4 | $302K | Buy |
40,600
+11,400
| +39% | +$77.5K | ﹤0.01% | 9234 |
|
|
2020
Q3 | $176K | Buy |
29,200
+17,900
| +158% | +$89.9K | ﹤0.01% | 9569 |
|
|
2020
Q2 | $71K | Buy |
+11,300
| New | +$52.3K | ﹤0.01% | 9647 |
|
|
2019
Q4 | – | Sell |
-25,600
| Closed | -$163K | – | 9818 |
|
|
2019
Q3 | $163K | Sell |
25,600
-92,600
| -78% | -$778K | ﹤0.01% | 9264 |
|
|
2019
Q2 | $1.06M | Sell |
118,200
-19,100
| -14% | -$150K | ﹤0.01% | 5508 |
|
|
2019
Q1 | $1.3M | Buy |
137,300
+120,960
| +740% | +$1.09M | ﹤0.01% | 4500 |
|
|
2018
Q4 | $105K | Buy |
16,340
+14,060
| +617% | +$94K | ﹤0.01% | 8194 |
|
|
2018
Q3 | $11K | Buy |
+2,280
| New | +$5.61K | ﹤0.01% | 9040 |
|
|
2015
Q3 | – | Sell |
-2,840
| Closed | -$55K | – | 9669 |
|
|
2015
Q2 | $55K | Sell |
2,840
-6,080
| -68% | -$209K | ﹤0.01% | 9856 |
|
|
2015
Q1 | $439K | Buy |
+8,920
| New | +$212K | ﹤0.01% | 7330 |
|
Other funds holding CRMD
DTC
VCM
RA
OAM
VPM
Susquehanna International Group's CRMD Position: Q1 2026 in Review
Susquehanna International Group reduced its CorMedix (CRMD) stake by 47% in Q1 2026, selling an estimated $1M and leaving 153,510 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #7785.
Susquehanna International Group first reported a position in CRMD in Q2 2015 and has held it in 39 quarters since. The position peaked at $5.22M in Q3 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.
- Susquehanna International Group held 153,510 shares of CorMedix worth $1.04M as of Q1 2026.
- Susquehanna International Group sold 135,374 CorMedix shares in Q1 2026, an estimated $1M.
- CorMedix made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7785 holding.
- Susquehanna International Group first reported a position in CorMedix in Q2 2015 and has held it in 39 quarters since.
- Susquehanna International Group's CorMedix position peaked at $5.22M in Q3 2025.
- 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.